GlobeNewswire by notified

Adoption of Resolutions of the Annual General Meeting of Shareholders of AS PRFoods Without Convening the Meeting

Share

The Management Board of AS PRFoods (registry code 11560713, address Harju County, Tallinn, Kesklinna District, Pärnu mnt 141, 11314; ISIN EE3100101031) proposes to the shareholders to adopt resolutions without convening a meeting in accordance with § 2991 of the Commercial Code.

Questions pertaining the draft decisions are to be sent via e-mail to investor@prfoods.ee or via regular mail to AS PRFoods to Pärnu mnt 141, 11314 Tallinn, Estonia no later than 22.12.2021. Relevant questions and answers will be published on the website of AS PRFoods www.prfoods.ee. The list of shareholders entitled to vote will be fixed on 22.12.2021 at the end of the business day of the Nasdaq CSD settlement system. As at the publication of this notice, the share capital of AS PRFoods is 7,736,572 euros. AS PRFoods has 38,682,860 ordinary shares, each share giving 1 vote at the general meeting. The voting period lasts from 23.12.2021 to 29.12.2021 (incl.). If a shareholder abstains from voting, the shareholder shall be deemed to have voted against the resolution. The voting ballot is available on the website of AS PRFoods www.prfoods.ee.

A shareholder has the following options to cast the vote:

(i) By sending the voting ballot filled in and digitally signed by the shareholder or signed and scanned by the voting shareholder or by the authorized representative via e-mail to investor@prfoods.ee during the voting period.

(ii) By submitting or sending the voting ballot filled in and signed by the shareholder entitled to vote or by the shareholder’s representative to the office of AS PRFoods at Pärnu mnt 141, 11314 Tallinn, Estonia so that it arrives no later than at 17:00 PM on 29.12.2021.

In order to verify the identity of a shareholder, the voting ballot sent via e-mail must be digitally signed. If sending a signed and scanned voting ballot via e-mail or sending a voting ballot by post, a copy of the personal data page of the shareholder's or shareholder's representative's identity document (e.g. passport or ID card) (incl. the document’s validity date) shall be sent with the voting ballot. The shareholder's representative shall also submit a valid power of attorney in Estonian or English language in a reproducible form. A shareholder may use the proxy template available on the website of AS PRFoods www.prfoods.ee. A shareholder who is a legal person registered in a foreign country, shall submit a copy of the extract from the corresponding foreign commercial register, which shows the right of the representative to represent the shareholder (legal authorization). The extract must be in English or translated into Estonian or English by a sworn translator or an official equivalent to a sworn translator.

The proposals of the Management Board approved by the Supervisory Board regarding the decisions to be adopted are the following:

1. Approval of the annual report of AS PRFoods for the financial year of 2020/2021

The proposal of the Supervisory Board of AS PRFoods is to approve the annual report of AS PRFoods for the financial year of 2020/2021.

2. Confirmation of the loss of AS PRFoods for the financial year 2020/2021 and decision to cover the loss

The proposal of the Supervisory Board of AS PRFoods is to confirm the loss for the financial year 2020/2021 in the amount of 5,069 thousand euros and to cover the loss as follows:

a) 51 thousand euros from statutory capital reserve;
b) 5,018 thousand euros from share premium.

3. Appointment of the auditor for the financial year 2021/2022 and determination of the auditor's fee

The Supervisory Board of AS PRFoods proposes to approve the audit company KPMG Baltics OÜ (registry code 10096082) as the auditor of AS PRFoods for the financial year 2021/2022 and to pay the audit company for the audit in accordance with the agreement to be entered into with KPMG Baltics OÜ.

As of the publication of this notice, the shareholders can acquaint with the materials of the general meeting, draft resolutions and other documents of the general meeting on the website of AS PRFoods www.prfoods.ee and on the website of the Estonian branch of NASDAQ CSD SE www.nasdaqbaltic.com.

The resolutions adopted by the shareholders will be published as a stock exchange announcement and on the website of AS PRFoods according to the Article 2991(6).

Indrek Kasela

Member of the Management Board of AS PRFoods


Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Verisk Welcomes Olumide Soroye to Its Board of Directors18.8.2022 22:15:00 CEST | Press release

JERSEY CITY, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK) today announced that Olumide Soroye has been appointed independent director of the company’s Board of Directors effective immediately. Soroye brings three decades of leadership experience across multiple industries. “Olumide’s experience in software, data analytics, AI, and growth-minded leadership make him an exceptional addition to Verisk’s board,” Verisk CEO Lee Shavel said. “We look forward to working closely with Olumide to ensure that we continue to drive value and positive impact for all Verisk stakeholders including shareholders, clients, employees and partners.” Soroye, 50, is president and chief executive officer of Fortive Corporation’s Intelligent Operating Solutions segment. Before Fortive, he held leadership roles at CoreLogic, where he was managing director of property intelligence & risk management, and QuinStreet, where he was senior vice president of the company’s technology and home services b

Galapagos receives transparency notification from FMR LLC18.8.2022 22:01:00 CEST | Press release

Mechelen, Belgium;18 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 15 August 2022 from FMR LLC, who notified that it holds 3,740,842 of Galapagos’ voting rights, consisting of 3,740,842 ordinary shares. FMR LLC controls investment funds FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,303,128 voting rights, and no longer holds any equivalent financial instruments, and Strategic Advisers LLC decreased its position to 10,082 voting rights. FMR LLC's holding of 3,740,842 Galapagos' voting rights represents 5.69% of Galapagos' currently outstanding 65,728,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos’ voting rights considering the

Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines18.8.2022 20:24:11 CEST | Press release

U.S. FDA approved facility operated by Grand River Aseptic Manufacturing will assist in filling of already manufactured bulk vaccine to expedite deliveries of monkeypox vaccines to the U.S.Agreement will significantly expand Bavarian Nordic’s manufacturing capacity for the benefit of the U.S. and globallyExpedited tech transfer has already started, allowing for manufacturing of first doses in 2022 COPENHAGEN, Denmark, August 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a U.S. based contract manufacturer, for fill and finish of JYNNEOS smallpox/monkeypox vaccine. As announced on July 15, 2022, Bavarian Nordic received an additional order for 2.5 million doses the vaccine from the U.S. Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR), which will be filled at GRAM using bulk vaccine already ma

Bavarian Nordic udvider produktionskapaciteten via aftale med amerikansk kontraktproducent om fyldning af koppe-/abekoppevacciner18.8.2022 20:24:11 CEST | pressemeddelelse

Den FDA-godkendte kontraktproducent, Grand River Aseptic Manufacturing, vil bistå med fyldning af allerede produceret råvaccine med henblik på at fremskynde leverancer af abekoppevacciner til USAAftalen vil øge Bavarian Nordics produktionskapacitet markant til gavn for både USA og lamde globaltEn accelereret procesoverførsel er allerede startet, hvilket muliggør produktion af de første doser i 2022 KØBENHAVN, Danmark, 18. august 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en aftale med den amerikanske kontraktproducent Grand River Aseptic Manufacturing (GRAM) om fyldning af JYNNEOS koppe-/abekoppevaccine. Som meddelt den 15. juli 2022, modtog Bavarian Nordic en yderligere ordre på 2,5 mio. doser af vaccinen fra U.S. Biomedical Advanced Research and Development Authority (BARDA), en del af Administration for Strategic Preparedness and Response (ASPR), som vil blive påfyldt på GRAMs facilitet ved brug af den råvaccine, der allerede er fremstillet og fa

PCI Biotech: Company update18.8.2022 18:05:06 CEST | Press release

Oslo (Norway), 18 August 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharma company developing innovative therapeutics that address significant unmet medical needs, today announced that the previously reported efforts to finance a planned Ph II trial in head and neck cancer have not under the current market conditions resulted in a feasible way forward. As PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology a reduction of the clinical team will be enacted during the second half of 2022. Further details about the development plans for the non-clinical assets will be given at the upcoming Q2 reporting, scheduled 31st August 2022. The cash position per Q2 2022 is around NOK 76 million and the financial runway is estimated to be towards the end of 2023. Contact information: Ronny Skuggedal, Interim CEO rs@pcibiotech.no Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutical company focusing on development and commercialisatio